Supplementary Figure S3 from Targeted Therapy of ≪i>tert</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy Jingwei Chen , Christopher P. Nelson , Matthew Wong , Andrew E. Tee , Pei Y. Liu , Ting La , Jamie I. Fletcher , Alvin Kamili , Chelsea Mayoh , Christoph Bartenhagen , Toby N. Trahair , Ning Xu , Nisitha Jayatilleke , Marie Wong , Pei Hui , Bernard Atmadibrata , Belamy B. Cheung , Qing Lan , Tracy M. Bryan , Pieter Mestdagh , Jo Vandesompele , Valérie Combaret , Valentina Boeva , Jenny Wang , Isabelle Janoueix-Lerosey , Mark J. Cowley , Karen L. MacKenzie , Alla Dolnikov , Jinyan Li , Patsie Polly , Glenn M. Marshall , Roger R. Reddel , Murray D. Norris , Michelle Haber , Matthias Fischer , Xu Dong Zhang , Hilda A. Pickett , Tao Liu openalex（2023）
摘要
Supplementary Figure S3. Screening for Approved Oncology Drugs (AODs) exerting synergistic anticancer effects with BET bromodomain inhibitors against TERT-rearranged neuroblastoma cells.
更多 查看译文
AI 理解论文
溯源树
样例
